CG
ADMA icon

Cutler Group’s ADMA Biologics ADMA Stock Holding History

Cutler Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,000
Closed -$7K – 3682
2022
Q4 		$7K Hold
2,000
– – ﹤0.01% 2904
2022
Q3 		$4K Buy
+2,000
New +$4.8K ﹤0.01% 3743
2022
Q1 		– Sell
-29,522
Closed -$41K – 5217
2021
Q4 		$41K Buy
29,522
+400
+1% +$526 ﹤0.01% 2545
2021
Q3 		$32K Sell
29,122
-17,859
-38% -$25K ﹤0.01% 2906
2021
Q2 		$75K Sell
46,981
-2,462
-5% -$4.33K ﹤0.01% 2125
2021
Q1 		$87K Buy
49,443
+47,193
+2,097% +$108K ﹤0.01% 1880
2020
Q4 		$4K Buy
+2,250
New +$4.73K ﹤0.01% 3741
2019
Q4 		– Sell
-900
Closed -$4K – 3898
2019
Q3 		$4K Hold
900
– – ﹤0.01% 3119
2019
Q2 		$3K Hold
900
– – ﹤0.01% 3323
2019
Q1 		$3K Buy
+900
New +$3.18K ﹤0.01% 3141

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Cutler Group's ADMA Position: Q1 2023 in Review

Cutler Group sold out of ADMA Biologics (ADMA) in Q1 2023, closing a stake of 2,000 shares — an estimated $7K sold.

Cutler Group first reported a position in ADMA in Q1 2019 and held it in 10 quarters. The position peaked at $87K in Q1 2021. 163 funds tracked by Wall St. Rank hold ADMA as of Q1 2023.

  • Cutler Group reported no remaining ADMA Biologics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 2,000 ADMA Biologics shares in Q1 2023, an estimated $7K.
  • Cutler Group first reported a position in ADMA Biologics in Q1 2019 and held it in 10 quarters.
  • Cutler Group's ADMA Biologics position peaked at $87K in Q1 2021.
  • 163 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.